These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 23200699

  • 1. Cytokine inhibition as a strategy for treating systemic lupus erythematosus.
    Clark DN, Markham JL, Sloan CS, Poole BD.
    Clin Immunol; 2013 Sep; 148(3):335-43. PubMed ID: 23200699
    [Abstract] [Full Text] [Related]

  • 2. Recent advances in cytokines in cutaneous and systemic lupus erythematosus.
    Mikita N, Ikeda T, Ishiguro M, Furukawa F.
    J Dermatol; 2011 Sep; 38(9):839-49. PubMed ID: 21767292
    [Abstract] [Full Text] [Related]

  • 3. Anticytokine therapy in systemic lupus erythematosus.
    Yoo DH.
    Lupus; 2010 Oct; 19(12):1460-7. PubMed ID: 20947558
    [Abstract] [Full Text] [Related]

  • 4. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.
    López P, Gómez J, Prado C, Gutiérrez C, Suárez A.
    J Rheumatol; 2008 Aug; 35(8):1559-66. PubMed ID: 18597405
    [Abstract] [Full Text] [Related]

  • 5. Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL+/+ and NZB/W F1 lupus-prone mice.
    Alleva DG, Kaser SB, Beller DI.
    J Immunol; 1997 Dec 01; 159(11):5610-9. PubMed ID: 9548504
    [Abstract] [Full Text] [Related]

  • 6. Pathogenesis of rheumatoid arthritis: targeting cytokines.
    Zwerina J, Redlich K, Schett G, Smolen JS.
    Ann N Y Acad Sci; 2005 Jun 01; 1051():716-29. PubMed ID: 16127012
    [Abstract] [Full Text] [Related]

  • 7. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
    Fleischer V, Sieber J, Fleischer SJ, Shock A, Heine G, Daridon C, Dörner T.
    Arthritis Res Ther; 2015 Jul 17; 17(1):185. PubMed ID: 26183319
    [Abstract] [Full Text] [Related]

  • 8. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
    Higgs BW, Zhu W, Richman L, Fiorentino DF, Greenberg SA, Jallal B, Yao Y.
    Int J Rheum Dis; 2012 Feb 17; 15(1):25-35. PubMed ID: 22324944
    [Abstract] [Full Text] [Related]

  • 9. Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosus.
    Dayan M, Segal R, Mozes E.
    J Rheumatol; 1997 Jun 17; 24(6):1075-82. PubMed ID: 9195512
    [Abstract] [Full Text] [Related]

  • 10. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA.
    J Rheumatol; 1997 Feb 17; 24(2):303-8. PubMed ID: 9034987
    [Abstract] [Full Text] [Related]

  • 11. Cytokine disturbances in systemic lupus erythematosus.
    Jacob N, Stohl W.
    Arthritis Res Ther; 2011 Jul 06; 13(4):228. PubMed ID: 21745419
    [Abstract] [Full Text] [Related]

  • 12. Treatment of systemic lupus erythematosus: new advances in targeted therapy.
    Lo MS, Tsokos GC.
    Ann N Y Acad Sci; 2012 Jan 06; 1247():138-52. PubMed ID: 22236448
    [Abstract] [Full Text] [Related]

  • 13. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice.
    Chae BS, Shin TY, Kim DK, Eun JS, Leem JY, Yang JH.
    Arch Pharm Res; 2008 Apr 06; 31(4):503-10. PubMed ID: 18449509
    [Abstract] [Full Text] [Related]

  • 14. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response.
    Lacki JK, Leszczynski P, Kelemen J, Müller W, Mackiewicz SH.
    J Med; 1997 Apr 06; 28(1-2):99-107. PubMed ID: 9249616
    [Abstract] [Full Text] [Related]

  • 15. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus.
    Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, Sysa-Jedrzejowska A.
    Br J Dermatol; 2008 Nov 06; 159(5):1124-30. PubMed ID: 18764842
    [Abstract] [Full Text] [Related]

  • 16. New treatments for SLE: cell-depleting and anti-cytokine therapies.
    Anolik JH, Aringer M.
    Best Pract Res Clin Rheumatol; 2005 Oct 06; 19(5):859-78. PubMed ID: 16150407
    [Abstract] [Full Text] [Related]

  • 17. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
    Enghard P, Langnickel D, Riemekasten G.
    Scand J Rheumatol; 2006 Oct 06; 35(3):209-16. PubMed ID: 16766368
    [Abstract] [Full Text] [Related]

  • 18. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain.
    Alleva DG, Kaser SB, Beller DI.
    J Immunol; 1998 Dec 15; 161(12):6878-84. PubMed ID: 9862720
    [Abstract] [Full Text] [Related]

  • 19. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
    Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G.
    J Rheumatol; 2002 Mar 15; 29(3):482-6. PubMed ID: 11908560
    [Abstract] [Full Text] [Related]

  • 20. Cytokines and their receptors as biomarkers of systemic lupus erythematosus.
    Suh CH, Kim HA.
    Expert Rev Mol Diagn; 2008 Mar 15; 8(2):189-98. PubMed ID: 18366305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.